to hydroxyethylurea protease inhibitors 447 contributions of the observed substitutions to drug resistance is presented in molecular modelling studies.
Introduction
The indispensability of the human immunodeficiency virus type 1 (HIV-1) aspartyl protease in the HIV lifecycle makes it an attractive target for the development of antiretroviral agents. Encoded within the Gag-Pol precursor, HIV protease catalyses the specific cleavage of the Gag and Gag-Pol polyproteins which releases the proteins and enzymes involved in virion formation and replication (Farmerie et al., 1987; Graves et al., 1988; Lillehoj et al., 1988; Mous et al., 1988) . The protease-mediated maturation of the polyproteins occurs as the immature virus particles bud from infected cells. Disruption of protease activity through site-directed mutagenesis (Kohl et al., 1988; Le Grice et al., 1988; Mous et al., 1988; Gottlinger et al., 1989) or inhibitor interaction (Kotler et al., 1988; Seelmeier et al., 1988) has been shown to result in improper processing of the viral polyproteins and the production of non-infectious virus particles. Since the protease functions at a late stage in the HIV life-cycle, protease inhibitors, unlike inhibitors of HIV reverse transcriptase (RT) , are effective against both productively infected cells and newly infected cells (Lambert et al., 1992) .
The protease molecule is a C2-symmetrical homodimer consisting of two 99 amino acid subunits each of which contribute an Asp residue (D25) to form the catalytic site (Pearl & Taylor, 1987) . To date, a variety of potent, substrate-based protease inhibitors have been described, several of which have been reported to reduce viral load within HIV-infected individuals (for example Ro 31-8959; Schapiro et al., 1996; L735,524; Condra et al., 1995;  ABT538; Danner et al., 1995; Markowitz et al., 1995a; and AG1343; J Peterkin et al. Randomized phase II studies of viracept, an HIV protease inhibitor given as monotherapy
Summary
In vitro resistance to the human immunodeficiency virus (HIV) protease inhibitors SC-52151 and SC-55389A was evaluated in an in vitro sequential selection scheme. HIV RF variants were selected for reduced sensitivity to SC-52151 and subsequently passaged in both SC-52151 and a structurally different hydroxyethylurea protease inhibitor, SC-55389A, to select for dualresistant virus. SC-52151 selection alone resulted in a 23-fold reduction in virus sensitivity whereas selection in both inhibitors resulted in 34-and eightfold reductions in virus sensitivity to SC-52151 and SC-55389A, respectively. Sequence analysis of the protease gene revealed that SC-52151-resistant virus had a Gly to Val substitution at residue 48 (G48V) and, in 58% of subclones, an accompanying Val to Ala substitution at residue 82 (V82A). Dual-resistant virus had both G48V and V82A substitutions present and, in the majority of subclones, an lie to Thr and/or Leu to Pro substitution at residues 54 and 63, respectively. Drug susceptibility assays with limiting dilution-cloned HIV RFR (G48V/ V82A) and HIVRF R (G48V/154T/L63P/V82A) viruses demonstrated mo~erate to high-level cross-resistance to additional structurally non-related protease inhibitors. Recombinant HIV HXB2 proviral clones with G48V, L63P and V82A substitutions showed that one active site mutation was permissible, but the presence of both G48V and V82A substitutions together significantly reduced infectious virus production. Insight into the and in combination with stavudine (d4T). 9th International Conference on Antiviral Research, Fukushima, Japan, 1996) . Yet protease inhibitor-based therapeutic strategies, like those involving RT inhibitors, must contend with the issue of in vivo viral resistance. To address this issue, in vitro selection studies using a variety of structurally non-related protease inhibitors have been performed in order to select protease inhibitor-resistant HIV variants. The results of these in vitro selection studies suggest that the majority of resistance mutations occur within the active site of the protease enzyme at residues 32, 48, 82 and 84 (Otto et al, 1993; El-Farrash et al, 1994; Kaplan et al, 1994; Jacobsen et al, 1995; King et al., 1995a; Markowitz et al, 1995b; Patick et al, 1995 Patick et al, , 1996 Tisdale et al., 1995) . However, amino acid substitutions located outside the active site may also confer resistance, as demonstrated for the hydroxyethylureaisostere-containing inhibitor SC-55389A, which selected for an Asn to Ser substitution at residue 88 (Smidt et al., 1997) .
Here we report the results of an in vitro sequential selection scheme using SC-52151 and SC-55389A which led to the isolation of dual-resistant HIV variants with two active site mutations. Cross-resistance profiles of the dualresistant variants were evaluated and the compatibility of the active site mutations was examined by molecular reconstruction of the observed changes in a HIVHXB2 proviral clone.
Materials and Experimental Procedures

Cells and virus
HIV RF and the CEM-T4, HeLa-CD4-LTR-~-galand MT-2 cell lines were obtained through the NIH AIDS Research and Reference Reagent Program (Rockville, Md., USA). The SW480 cell line was obtained through the ATCC (Rockville,Md., USA). The HIVHXB2 proviral clone pHXB2gpt2 was kindly provided by L Ratner (Washington University, St Louis, Mo., USA).
Compounds
The protease inhibitors SC-52151, SC-55389A, L735,524 and Ro 31-8959 were synthesized at Searle (Skokie, Ill. and St Louis, Mo., USA). The nucleoside analogue azidothymidine (AZT) was purchased from Burroughs Wellcome (Research Triangle Park, N.C., USA).
Sequential selection with HIV RF in CEM-T4 cells
CEM-T4 cells were infected with HIV RF [rn.o.i, 0.01, determined by RT assay as described previously (Bryant et al, 1995) ] and resuspended in RPMI plus 10% fetal bovine serum containing 0.02~LM SC-52151 for one passage. The effective concentration at which 50% of virus production is inhibited (EC so) for HIVRF is 0.03~M. 448 When virus replication (extensive cytopathic effect) was observed, supernatants were used to infect fresh CEM-T 4 cells and virus was grown in an increased concentration of inhibitor for the next passage. For sequential selection of dual resistant virus, SC-52151-resistant virus from passage 90 (2.0~M SC-52151) was used to infect CEM-T4 cells and virus was passaged as above in 0.8 ulvl SC-52151 and 0.9~LM SC-55389A for nine additional passages. SC-52151-resistant virus from passage 90 (P90) and dualresistant virus from passage 8 (PB8) were cloned by limiting dilution to yield viruses HIVRFR and HIVRFRR' respectively. Working stocks of HIVRFR and HIVRFRR were prepared and titrated using a HeLa-CD4-~-gal assay (Kimpton & Emerman, 1992) .
Drug susceptibility assays
Quantitative virus detection for the determination ofEC so for passaged virus was performed by RT assay on culture supernatants obtained from CEM-T4 cells infected with passaged virus as described previously (Bryant et al., 1995) . EC so values were calculated by fitting the four parameter logistic model (De Lean et al, 1978) using the SAS nonlinear modelling procedure to the obtained c.p.m. values for each inhibitor dilution series.
Sequence analysis of the protease gene
Cell pellets from infected cultures were resuspended in lysis buffer (10 mM Tris-HCI pH 8.3,2.5 mM MgCI 2 , 50 mM KCI, 0.5% Tween 20, 0.5% NP40, 120~g mL-l proteinase K) to a final concentration of2x10 6 cells mL-1 and incubated at 60·C for 1 hand 90"C for 10 min. A portion of lysed material was extracted with an equal volume of phenol: chloroform: isoamyl alcohol (25: 24 : 1) three times and precipitated. The pellet was washed with 70% EtOH, resuspended at one-third the original volume in H 2 0 and stored at -20"C. A 700 bp fragment which included the protease gene was amplified by PCR using primers POL2059 (5' GCGGAATTCGATTGTACT-GAGAGACAGGCTAA 3') and POL2727 (5' GCG-GAATTCTTCTTTATGGCAAATACTGGAGT 3'), which have EcoRI restriction sites incorporated into the 5' ends. PCR products were digested with EcoRI and subcloned into EcoRI -linearized M13mp18. Double-stranded DNA was purified from 1.5 mL of a 6 h culture using Qjawell 8 Plus (Qiagen) and sequenced using fluorescent dye-labelled terminators (Applied Biosystems) with primers NSP1 (5' AACAGCCCCACCAGAAGA 3') and NSP2 (5'CCTTCCTTTTCCATTTCTGTACA 3'). Sequencing samples were run on an ABI 373A automated DNA sequencer (Applied Biosystems) and sequences were edited in Sequencher 2.1 (Gene Codes, Ann Arbor, Mich., USA) and Mac DNAsis Pro 02-00 (Hitachi Software Engineering America, San Bruno, Calif, USA).
Construction of HIV HX B2 proviral clones
Single-stranded DNA of the pAlter plasmid (Promega) containing the 5.3 kb SaeI fragment of pHXB2gpt2 was purified for use in oligonucleotide-mediated site-directed mutagenesis of the protease gene using the Altered Sites in vitro Mutagenesis System (Promega). Mutated protease genes were cloned into pHXB2gpt2 as a 4.3 kb SpeI-SalI fragment and the provirus protease genotype was reconfirmed by DNA sequencing. Proviral clones were used to produce infectious virus by transfection of SW480 cells with 2 !J,g of proviral DNA in the presence of Lipofectin (Gibco BRL). After transfection, cells were incubated for 3 to 5 days at which point culture supernatants were used to infect MT-2 cells to produce virus master stocks. Working stocks of wild-type and mutant proviruses were grown on MT-2 cells and titrated using a HeLa-CD4-f3-gal assay (Kimpton & Emerman, 1992) . The protease genotype of working stock viruses was verified by DNA sequence analysis of the protease gene as described as above.
Growth and drug susceptibility assays with HIV HX B2 proviral clones
Growth kinetics and drug susceptibility assays were conducted simultaneously. Individual aliquots of MT-2 cells were infected with proviral mutant or wild-type parental virus (m.o.i. 0.02) and incubated at 3TC for 1 h. Infected cultures were spun down, resuspended in media, and infected cells were plated in triplicate in a 96-well format. Drug susceptibility wells contained threefold dilutions of SC-52151, SC-55389A, L735,524, Ro 31-8959 or AZT in the media while control wells contained media alone. Wells designated for viral growth analysis contained media without inhibitors. Plates were incubated at 3TC for up to 36 days. For both growth kinetics and drug susceptibility wells, 100 !J,L samples were removed at day 4 or day 7 and in 4 day intervals thereafter, and media or media contain-Resistance to hydroxyethylurea protease inhibitors ing inhibitor at the appropriate dilution was replaced. All samples were stored at -20°C.
Virus production was measured in an ELISA-based assay by detection of HIV p24 core antigen (Coulter). The means ofduplicate absorbance values obtained for each virus at each time point were used to calculate the corresponding p24 pg mL 1 values from the kinetic standard curve. EC so values were determined by fitting the calculated p24 pg mL-1 values for the inhibitor containing virus samples in the four parameter logistic model using the SAS non-linear modelling procedure. The limits for the upper plateau of each dose-response curve were defined as the median of the p24 pg mL-1 values obtained for each provirus from the media alone wells. Infectious virus production was determined by measurement of virus p.fu. mL-1.
Molecular modelling studies
Models of SC-52151 and SC-55389A binding to mutant enzyme were constructed based on structures ofwild-type HIV HXB2 enzyme complexed with SC-52694 (Getman et al., 1993) , a close analogue of SC-52151, and with SC-55389A (HS Shieh, WC Stallings &R Stegeman, unpublished results), respectively. The side chains at residues 48 and 148 and residues 82 and 182 were replaced with Val and Ala, respectively. Models were created using Insight software (BiosymlMolecular Simulations; San Diego, Calif., USA).
Results
Sequential selection for resistant virus
As part of ongoing laboratory studies to evaluate HIV-1 resistance profiles to multiple protease inhibitors, the potent hydroxyethylurea inhibitors SC-52151 and SC-55389A ( Fig. 1) were used in an in vitro sequential selec- tion experiment. Initially HIV-1 RF-infected CEM-T4 cells were passaged in the presence of 0.02~tM SC-52151, the concentration of which was gradually increased when extensive cytopathic effect was observed. Drug susceptibility assays were performed on harvested virus and compared to that observed for wild-type parental virus. At 1.7 tM SC-52151, a ninefold reduction (EC so 0.29~tM) in virus sensitivity to SC-52151 was observed in the P79 virus population. Further passage at 1.7 u.M SC-52151 selected virus at P90 which had a 23-fold reduction (EC so 0.76~tM) in susceptibility to SC-52151.
The protease genotype for the P79 and P90 virus populations was examined by nucleotide analysis of HIV DNA obtained from lysis of infected culture cell pellets. HIV DNA was amplified by PCR and the protease gene of multiple subclones was sequenced. The SC-52151 resistant virus isolated at P79 and P90 had an amino acid substitution at residue 48 and, in some subclones, a second substitution at residue 82 ( Fig. 2a) . In all but one of the P79 and P90 subclones examined, a G to T transversion replaced the Gly residue at 48 with Val. The one exception was a 450 Met (GGG~ATG) rather than a Val substitution at residue 48. The second most frequently observed amino acid change, an Ala for Val (GTC~GCC) substitution at residue 82, was present in 10/21 (48%) and 11/19 (58%) of the subclones from the P79 and P90 passages, respectively.
To select for HIV-1 variants with dual resistance to SC-52151 and SC-55389A, the SC-52151-resistant virus from P90 was used to infect fresh CEM-T4 cells which were subsequently passed in the presence of both 0.9~tM SC-55389A (EC so 0.07~tM) and 0.8~tM SC-52151. By the eighth passage, a viral population, PB8, with an eightfold reduced susceptibility (EC so 0.56~M) to SC-55389A and a 34-fold reduced susceptibility (EC so 1.14~tM) to SC-52151 was obtained. Sequence analysis of subclones of the SC-52151 and SC-55389A dual-resistant virus, PB8, showed that the V82A mutation, in addition to the G48V mutation, was present in 100% of the subclones (Fig. 2a ). Viral passage in both SC-52151 and SC-55389A also resulted in the selection of two additional mutations, a Leu to Pro (CTC~CCC) substitution at codon 63 in 16/19 (84%) subclones and an He to Thr (ATC~ACC) substi- observed for HIVRFR against SC-52151. HIVRFR was also shown to have moderate resistance to SC-55389A (10-fold), L735,524 (ninefold) and Ro 31-8959 (14-fold).
HIVRFRR was observed to demonstrate high-level crossresistance (>100-fold) to SC-52151, SC-55389A, L735,524 and Ro 31-8959 (Table 1) .
Characterization of HIV HX B2 provirel clones
The amino acid substitutions observed in the sequential selection experiment were constructed as single, double and triple mutations in the protease gene of an HIVHXB2 proviral clone in order to evaluate possible effects on viral growth and resistance phenotype. The growth kinetics for each HIVHXB2 protease mutant virus were examined' over an extended time period through the monitoring of p24 core antigen production in an ELISA-based p24 assay. Of the single mutant variants, the growth kinetics observed for the V82A virus was similar to that of wild-type HIVHXB2 virus, whereas the G48V virus was delayed (Fig.  3 ). Both the p24 assay and determination of infectious virus titre by measurement of p.f.u. mL-l showed that the G48VN82A and G48V/L63PN82A variants replicated poorly (,;;100 p.£u. mL-\ data not shown). EC so determinations for the G48V/V82A and G48V/ L63PN82A viruses were not done owing to the insufficient virus titres. EC so values for the wild-type, V82A and G48V engineered HIVHXB2 protease mutant viruses against SC-52151, SC-55389A and AZT were determined at comparable times within each virus growth curve ( 
Drug susceptibility of isolated resistant variants
Viruses obtained at P90 and PB8 were cloned by limiting dilution. Working stocks were prepared and the viral genotypes were examined by sequencing subcloned, amplified viral DNA. The HIVRFR working stock virus, which was cloned from the SC-52151-resistant P90 virus population, had both the G48V and V82A substitutions present in all subclones examined (15/15; Fig. 2b ). HIVRFRR' the working stock virus cloned from the dual resistant PB8 virus, was homogeneous for the G48V, I54T, L63P and V82A substitutions. Drug susceptibility assays on the HIVRFR and HIVRFRR stocks were performed and the fold shifts relative to HIVRF are shown in Table 1 . High-level resistance, ;,,70-fold reduction in virus susceptibility, was Proviruses are designated by the predicted amino acid substitutions present within the protease gene and HIV HXB2 is designated as wild-type. Cells were infected at day 0 and samples were taken at day 4 or at day 7 and in 4 day intervals thereafter.
tution at codon 54 in 8/19 (42%) subclones. In subclones where the I54T substitution was observed, the L63P substitution was also present.
KE Potts et aI.
Fi9u~e~. Models of HIVprotease-inhibitor interactions in wild-type HIV HXB2 enzyme containing G48V and V82A substitutions.
(a) Interactions of the protease flap with 5C-52694, which is a close analogue of 5C-52151. Also depicted is hydrogen bond formation between the protease backbone and a cluster of water molecules. (b) Interactions of protease residue positions 48 and 82 with a model of 5C-52151, based on the crystal structure complex with 5C-52694. A Connolly surface of the G48 and V82 side chains is shown in red. The side chain surfaces for the mutated side chains, V48 and A82, are shown in yellow.
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© 1997 Inlernational Medical Press Ltd > low-level (four-to sixfold) resistance to both SC-52151 and SC-55389A while moderate (12-to 17-fold) resistance to SC-52151 was observed with the G48V variant.
Molecular modelling studies
Crystallographic information for the wild-type protease can be used to understand the role of the G48V substitution in resistance conferred against SC-52151. A model of SC-52151 was constructed based on the crystal structure determined for a related compound, SC-52694 (Getman et al., 1993) . The model indicates that the G48 residue positioned near the S2'-S3' subsites makes no close contacts with the inhibitor. By contrast, the G48 residue from the opposing chain is positioned near the S2-S3 quinolinyl-2-carbonyl-L-asparaginyl (Q:Asn) moiety of the inhibitor, makes close contacts with the inhibitor and forms a solvent network at the surface of the enzyme. The G48 position may therefore be key in mediating resistance, as this residue makes a number of interactions with the inhibitor and surrounding environment. The carbonyl oxygen of G48 favourably interacts with the amide nitrogen that bridges the P2' and P3' groups (though slightly longer than the hydrogen bond distance), and is also in close contact with the carbonyl of the P2' Asn moiety. The main chain nitrogen of residue 48 forms a hydrogen bond with a water molecule that leads to a solvent network near the surface of the enzyme. The G48V and V82A substitutions are shown in Fig.  4 , where the substitutions have been made in the absence of any other modifications to the crystal structure. A Val substitution at position 48 would, depending on its conformation, sterically interfere with the Q:Asn moiety of the inhibitor or with the F53 side chain.
While the effect of the V48-quinoline interaction may directly influence inhibitor binding via unfavourable van der Waals interactions, the effect on the F53 side chain may be more indirect. The close proximity of the side chains at V48 and the F53 side chain may cause perturbations in the flap conformation. These changes could adversely affect hydrogen bonding and other interactions between the inhibitor and the flap. Perturbations in the flap conformation could also influence the dynamics of the flap residues.
Structural information has also been used to analyse the effect of the V82A substitution on the binding of SC-55389A and SC-52151. The residue at position 82 forms part of the hydrophobic lining of the S1 and S1' subsites. Our crystal structure information for the hydroxyethylurea series demonstrates that SC-52151 and SC-55389A makes contacts with V82 through the benzyl groups of the inhibitors at S1 and the t-butyl groups of the inhibitors at S1'. Replacement of Val at position 82 by a smaller hydrophobic residue would lead to reduced sensitivity to Antiviral Chemistry &Chemotherapy 8 (5) Resistance to hydraxyethylurea pratease inhibitors both SC-55389A and SC-52151 as a result of decreased hydrophobic protease-inhibitor contacts in the S1 and S1' subsites.
Discussion
The initial passage of HIVRF in increasing SC-52151 concentrations followed by the passage of the SC-52151selected virus in both SC-52151 and SC-55389A led to the isolation of HIVRFR and HIVRFRR' respectively. Each mutant exhibited moderate to high-level resistance to SC-52151, SC-55389A, L735,524 and Ro 31-8959. DNA sequence analysis of the protease gene identified two active site mutations, G48V and V82A, present in both HIV RFR and HIV RFRR . The HIV RFRR variant also contained I54T and L63P substitutions. The selection of viral variants with G48V substitutions within the protease gene has been demonstrated to occur both in vitro (Jacobsen et al., 1995; Tisdale et al., 1995) and in vivo (Schapiro et al., 1996) using Ro 31-8959. In such instances, the G48V substitution was usually accompanied by a L90M substitution; however, the frequency with which the 48 or 90 amino acid substitution was detected differed in vitro and in vivo (Schapiro et al., 1996) . In contrast to the G48V substitution, in vitro isolation of V82A-substituted resistant variants has been reported for several structurally non-related protease inhibitors (Otto et al., 1993; Patick et al., 1995; Tisdale et al., 1995) . The SC-52151, SC-55389A selection strategy presented in this report has led to the selection of dual-resistant variants with both G48V and V82A substitutions. The selection of G48VN82A-substituted variants has been recently reported in an in vitro sequential selection strategy with BMS 186,318-resistant virus (Rose et al., 1996) .
In that study, subsequent passage of an A71T N82A BMS 186,318-resistant virus population in SC-52151 or Ro 31-8959 led to the selection of resistant virus populations with predominant changes at V13I/G48V/A71T/V82A and G48VI154VI A71TN82A, respectively.
The recreation of the G48V substitution in an HIVHXJl2 proviral clone was found to confer 12-to 15fold reduction in virus sensitivity to SC-52151. These data support our in vitro selection observations in which G48V was found to be the most prevalent amino acid substitution present in the virus population passaged in inC1'~asing concentrations of SC-52151. Since G48V-substltuted proviruses have been reported to demonstrate reduced susceptibility to Ro 31-8959 (Jacobsen et al., 1995; Maschera et al. 1995) , it was expected that HIV RFR and HIVRFRR viruses, both of which contain G48V substitutions in addition to other amino acid changes, would demonstrate Ro 31-8959 resistance. Similarly, HIVRFR and HIVRFRR cross-resistanc:e to L735,524 was expected since reduced susceptibility to L735,524 has been demonstrated for a V82A variant upon acquisition of two additional active site mutations and one remote mutation (Tisdale et al., 1995) . It is possible that the presence of the second active site mutation at residue 48 may result in further perturbations in L735,524 binding caused by the V82A substitution.
Residue 48 is located within the flap region of each protease subunit and is part of a conserved IGGIGG motif spanning residues 47-52 (Pearl & Taylor, 1987; Loeb et al., 1989) . Mutagenesis within this region has shown that G48 is the only residue tolerant of specific charged as well as hydrophobic substitutions without significant adverse effects on enzyme activity (Loeb et al., 1989) . Structural analysis of the enzyme interactions with SC-52151 suggest that a G48V substitution may perturb SC-52151 binding in the S2-S3 subsites. This hypothesis is consistent with the present experiments which demonstrate that the HIVRFR and HIVRFRR viruses are less sensitive to Ro 31-8959, which, like SC-52151, contains a Q:Asn group that spans the P2-P3 moiety. The mobility of the flap regions may also be affected by a G48V substitution. Comparisons of crystal structures and molecular dynamics calculations suggest that the IGGIGG motif may be flexible (Collins et al., 1995) . The mobility of the flap residues is critical for allowing substrates and inhibitors access to the active site. The G48V substitution would be expected to alter the flexibility of the flap and could thereby reduce the catalytic efficiency of the variant enzyme as well as its sensitivity to inhibitors.
The contribution of a V82A substitution to SC-52151 resistance is inferred by its presence in the P79 virus population and small increases in its representation (48 to 58%) and SC-52151 susceptibility (9-23x) in the P90 virus population. The addition of SC-55389A to the SC-52151 selection was observed to increase the presence of the V82A substitution from 58 to 100% in the dualresistant virus population, PB8. When recreated in the HIVHXB2 provirus, V82A was observed to confer low-level resistance to both SC-52151 and SC-55389A.
The structural analysis suggests that replacement of Val at residue 82 with a smaller hydrophobic Ala residue would lead to reduced sensitivity to both SC-55389A and SC-52151 as a result of decreased hydrophobic protease-inhibitor contact in both the Sl and Sl' subsites. The structure of the symmetric C2 inhibitor, A770m, complexed with a V82A protease variant is in general consistent with this hypothesis, although the Sl and Sl' pockets are asymmetric and relatively tight hydrophobic interactions are maintained in the Sl subsite (Baldwin et al., 1995) . A reduction in both enzyme substrate affinity and catalytic cleavage activity was reported for a V82A variant with BMS 186,318 (Patick et al., 1995) . In this instance, enzyme substrate affinity was restored to the wild-type 454 level by the presence of an accompanying A71T substitution, but at the expense of reduced cleavage activity. Whether the two additional substitutions, I54T and L63P, which were observed to dominate the majority of the selected dual SC-52151 and SC-55389A resistant virus population, compensate at the enzyme level for the effects of the V82A and/or G48V substitutions in a manner similar to that seen with the A71TN82A variant is unknown.
However, the I54T and/or L63P substitutions do contribute to viral resistance as seen in the increased crossresistance of HIVRFRR virus relative to that demonstrated by HIVRFR' Accompanying substitutions at residue 54 (I54V and I54N) were also reported for the G48V/A71TN82A dual BMS 186,318 and Ro 31-8959 resistant virus population (Rose et al., 1996) . Insight into the molecular basis for the increased cross-resistance observed for the I54T and L63P substitutions present in HIVRFRR as well as the cross-resistance conferred by simultaneous G48V and V82A substitutions may be gained through the resolution of crystal structures for these proteases complexed with different inhibitors. Efforts are currently underway to determine G48VN82A protease-inhibitor structures.
The poor growth of the reconstructed G48VN82A HIVHXB2 variants relative to that observed for the HIVRF virus which was used in the initial in vitro selection strategy suggests that amino acid differences within the protease enzyme and/or outside this region may influence the ability of specific amino acid substitutions within the active site of the protease to be tolerated. The importance of viral background was demonstrated in the BMS 186,318 study where the inclusion of an L10I substitution significantly improved the growth kinetics of a G48V/A71TN82A HIV NlA _ 3 variant (Rose et al., 1996) . It was of interest to note in our study that the inclusion of the L63P mutation in the G48V/L63PN82A HIVHXB2 mutant did not reduce the adverse effect of the G48VN82A substitution (data not shown). An L63P substitution has been previously reported to restore growth of an L10RlL63P/V82T1I84V provirus (Condra et al., 1995) .
The importance of viral background may also be inferred from the observation in a separate study with SC-55389A and SC-52151 (Smidt et al., 1997) , that isolated resistant variants were observed to have genotypes (N88S and M46I, F53L, A71V, N88D) different from those observed in the present study. This discrepancy is most likely a reflection of the starting virus population (different laboratory strains as well as clinical isolates) and the different in vitro selection conditions (inhibitor concentration and order of addition) that were used. Precedent for different in vitro selection parameters to select for genotypically distinct resistant variants was first reported with A77003 where either R8Q (Ho et a., 1994) or V32IN82I (Kaplan et al., 1994) resistant variants were isolated.
While in vitro selection studies have a limited ability to predict the magnitude of genotypic changes present in in vivo drug-resistant viral isolates, in vitro-selected resistant viruses are useful in examining cross-resistance to different classes of protease inhibitors. In this respect, the HIVRFR and HIVRFRR viruses are of particular value since the G48V and V82A substitutions are associated with viral resistance to protease inhibitors currently undergoing clinical trials. Insight into the contributions of these amino acid substitutions in conferring resistance to structurally non-related protease inhibitors may aid in the understanding of the effects of genetic variability on the development of cross-resistant HIV-l variants in vivo and design of combination antiviral therapies.
